The shift to specialty medicines has opened up for pharma companies a wealth of opportunities in addressing unmet medical needs of patients and improve the cost of care. This shift has also brought significant challenges, especially in the form of pricing and market access in an environment that is becoming increasingly resistant to higher cost drugs. This paper looks at the keys to success on how pharma companies will need to think differently to prepare for these specialty drug launches and the use of analytics to support pricing decisions.
Dr. George A. Chressanthis is currently Principal Scientist at Axtria. He brings a unique combination of professional experiences into the analysis of strategic and operational issues affecting the biopharmaceutical industry.
Contact us at insights@axtria.com for any questions.